Investing in diagnostics is key to unlocking broader health-system benefits
Over the next 25 years, antimicrobial resistance (AMR) is projected to cause up to 10 million deaths annually, and cost over $150 billion in economic losses. Our newest report finds that AMR diagnostics are essential in combatting this crisis, but their value is overlooked in policy frameworks and reimbursement decisions.
In this report, we introduce STRIDES, a conceptual framework to better assess the population-wide value of AMR diagnostics, adding seven AMR-specific dimensions to supplement existing frameworks. We explore how the value of AMR diagnostics goes beyond patient outcomes, with long-term benefits for the wider population and for health systems.
At OHE, we’re also working on understanding the wider value of precision diagnostics. Pharmacogenomics can reduce adverse drug reactions by 30%, potentially averting over £500 million in costs to the NHS. However, structural challenges to realising the potential of pharmacogenomics in the UK persist.
We’re one of the collaborators for the Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx), led by the University of Liverpool and funded by Innovate UK, with our work focusing on developing economic frameworks to assess the return on investment in pharmacogenomics.
